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ONE OF THE MORE INTERESTING CASES I WORKED ON AS
A YOUNG ASSOCIATE IN THE
EARLY 1980S INVOLVED GEORGE
STEINBRENNER, the well-known
owner of the New York Yankees. He
had invested in an oil and gas venture
in West Virginia aptly named Yankee
Energy. When the investment did not
pan out, he filed suit against a wide
array of defendants, including the West
Virginia driller, the tax accountant who
had worked on the deal, the attorney
who had put together the investment documents, as well as his own
personal financial advisor and assistant.
Steinbrenner claimed that the defendants had received improper kickbacks
and had taken other actions that were
fraudulent.
The case became one of those
scorched-earth lawsuits that have given
U.S. litigation a bad name. Scores
of depositions — some consisting of
more discussion and argument among
the lawyers than questions asked of
deponents — were taken around the
country, with most going for days if not
longer. At one point, there were over
100 discovery motions pending before
the district court.
In the middle of this procedural
morass, one of the defendants filed a
motion pursuant to Section 1407 to
consolidate the Steinbrenner case and
a handful of similar lawsuits involving other plaintiffs who had invested
with the same West Virginia oil and
gas driller. This was my first involvement with the multidistrict litigation
(MDL) process. It was not something
that was taught in either the basic Civil
Procedure or advanced Civil Procedure
courses that I had taken in law school.
My initial reaction was that these
cases probably were not the type of
complex, large-claim cases that surely
must make up the bulk of the MDL
docket. But in researching the MDL
process — which at that point had
only been around for a dozen years — I
was surprised that many of the MDL
dockets were in fact consolidations of a
relatively small number of cases. Indeed
the origins of the MDL process did not

define with any exactness the type of
cases that could be found suitable for
the process. While there were some
general categories of case types that
were identified as particularly appropriate, the MDL procedure was openended and could be applied widely
across the litigation spectrum.
We opposed the motion to consolidate, generally arguing that there were
too few cases to benefit from consolidation and that the cases had significant
factual variations. Also, our case was
already in the later stages of discovery
at the time of the Section 1407 filing.
The Judicial Panel on Multidistrict
Litigation (JPML) held a hearing on the
case in Seattle. Several attorneys from
Atlanta, Florida, and West Virginia
made the long trek to Seattle for a very
short 15-minute hearing. My opening
comment made some reference to the
Boston Red Sox not being forced to
move a game in the top of the seventh
inning (one of the panel judges was
from Massachusetts so it seemed appropriate in a case involving the Yankees).
The panel ultimately denied the motion
to consolidate. We continued to slog
through the trench warfare of discovery
until ultimately the case was settled
on the eve of trial. In retrospect, I still
wonder whether MDL consolidation
might have offered some benefits.
The experience demonstrated to me
— as it probably did to many litigators
during this time period — the potential importance of the MDL process.
If the Steinbrenner case had been
transferred, it could have significantly
impacted the handling of the case. A
new transferee judge could have established a new approach to discovery that
could have radically altered the dynamics of the case.
That the MDL process has grown
and evolved since those early days
is clear. The question is how it has
evolved. Is it still a general procedure
applicable across a wide range of litigation case types? Or are there particular litigation types that have come to
dominate the process as the currents of
litigation have changed over time?
This question is of particular impor-
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tance in the area of mass torts — those
personal-injury claims that can involve
hundreds or even thousands of victims
of a single alleged wrong.
The conventional wisdom is that
the MDL process is generally applicable to a wide range of litigation types,
and that mass torts can be included as
“one among many” types of lawsuits
potentially subject to the MDL process.
While one can view the MDL case
statistics to support that view, a more
careful examination of the MDL data
as it now stands reveals a very different
reality: Mass-tort claims have come
to dominate the MDL docket. This
growing trend raises questions as to
how mass torts are shaped, defined, and
ultimately resolved through the MDL
process. Given the enormous potential liability associated with mass-tort
claims, understanding the procedural
processing of these claims is both interesting and important.
Historical Overview
It is useful to provide a quick overview
of the origins of the MDL process focusing on the types of cases its proponents
envisioned as being particularly suitable
to its approach.
The MDL arose out of judicial experience with an extraordinary number
of antitrust cases filed by utilities,
municipalities, and others against the
manufacturers of electronic equipment.
Following a successful government
antitrust prosecution of manufacturers
of electrical equipment in the 1960s,
over 1,800 civil cases were filed in over
30 different federal court districts. The
discovery in those cases was extensive, and the potential for overlapping
depositions and document production
was obvious. To deal with this “wave of
litigation [that] threatened to engulf
the courts,” the Judicial Conference
of the United States recommended
the creation of a new “Coordinating
Committee for Multiple Litigation”
to recommend actions to control and
manage the cases.1
The Coordinating Committee
recommended a series of uniform
pretrial and discovery orders that each 4
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district court judge could apply to
the cases in their respective districts.
The uniform orders established rules
for centralized document depositories. These depositories made nearly
1 million documents available to the
parties. The coordinating efforts also
established the taking of “national”
depositions in which attorneys from
other cases could ask questions.
The consensus view was that the
actions taken by the Coordinating
Committee were greatly successful
in preventing the federal courts from
being overwhelmed by the electrical
equipment cases. By the same token,
many recognized that the coordinating
process itself had some inefficiencies,
as over 30 district court judges had
to arrange schedules and travel. Also,
because the efforts were voluntary, there
was the risk that in similar future cases,
some judges would not fully cooperate.
Accordingly, the Coordinating
Committee drafted legislation to
formalize a procedural tool to deal with
situations that might arise. As a result of
the recommendation, Congress in 1968
established the JPML and empowered
it to transfer groups of cases and assign
them to a judge for the “limited purpose
of conducting pretrial proceedings.” In
discussing what was encompassed in
this charge, the House report noted that
pretrial proceedings “generally involve
deposition and discovery” but that
under the federal rules additional steps
would be possible, including rendering
summary judgment, controlling and
limiting pretrial proceedings, and imposing sanctions for “failure to make discovery or comply with pre-trial orders.”2
After completion of the pretrial proceedings, the cases were to be remanded to
the district where they were originally
filed. There was never any expectation
that the transferee judge would actively
manage the case to consider a global
settlement, although it was understood
that some settlements may occur, such
as in cases where liability was clear. The
main focus for the transferee judge was
to oversee the discovery process with
the expectation that the cases would
ultimately be remanded for trial.
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It is surprising that the

description used for eligible cases was “massive
filings” — as if the

MDL process would be

reserved for a relatively

small number of actions.
Having only had the electrical
equipment “massive filings” as an
example to justify the new procedure,
it is interesting to consider what other
areas of litigation might have been
anticipated as especially likely to be
subject to the new process at the time
of the passage of the MDL procedures.
The legislative history set forth the
following as potential candidates for
MDL treatment:
“The types of cases in which massive
filings of multidistrict litigation are
reasonably certain to occur include not
only civil antitrust actions but also,
common disaster (air crash) actions,
patent and trademark suits, products
liability actions and securities law violation actions, among others.” 3

Given the scant history of similar
types of “massive filing” cases, this
description has a bit of an “I know
when I see it” feel to it. The electrical
equipment cases had revealed a potential
problem, and a simple solution had been
found. It is probably not fair to assert
that the MDL procedures were created
as a prophylactic measure only for the
extraordinary cases like the electrical
equipment cases, but it was anticipated
to be the exception rather than the rule.
Knowing what we now know of
the MDL process, it is surprising that
the description used for eligible cases
was “massive filings” — as if the MDL
process would be reserved for a relatively small number of actions that
fit the model of the electrical equipment cases. As the history of the MDL
process shows, this focus on “massive
filings” has been significantly relaxed.
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It is less surprising that the focus of
the anticipated use of the MDL process
was not more clearly centered on what
we have come to refer to as mass-tort
cases. When enacted in 1968, the
category of mass-tort cases was not well
understood. Of course, this was well
prior to the Agent Orange, Dalkon
Shield, and Bendectin litigations that
helped develop our appreciation for the
potential of mass-tort claims. In the
litigation world at the time, tort claims
that could potentially be suitable for
the new MDL process were imagined as
primarily “common disasters,” such as
airplane crashes, and, to a more limited
extent, product-liability cases.
Early Experience with the MDL Process
The MDL process quickly revealed that
it was not going to be limited to exceptional cases with “massive filings.” An
early study published in 1974 in the
Harvard Law Review detailed extensive
use of Section 1407.4 At the time of
the study, the panel had considered
148 actions under Section 1407 and
consolidated actions in 112 dockets for
a grant rate of 75 percent. As probably
anticipated, antitrust was the leading
area with 35 consolidations (31 percent
of the total dockets granted). Securities
cases — which interestingly was not
a category listed in the House report
— constituted 28 of the total dockets
created (25 percent). “Mass disasters”
(which were primarily airplane crash
cases) also constituted 28 of the dockets
that were transferred. The only other
category with a significant number of
MDL dockets created was patent/copyright cases (11 dockets constituting 10
percent of the total dockets granted).
Significantly, product-liability
cases — the category in which most of
the mass-tort cases would fall in our
current understanding of mass torts —
were negligible. The panel considered
only three potential product-liability
dockets during the first six years of its
operations; it denied transfer in two of
the three matters.
One of those three early MDL
product-liability cases is particularly
interesting in the evolution of the
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use of the MDL process for mass-tort
cases. In In re Oral Contraceptives Products
Liability Litigation,5 the JPML considered the possible consolidation of 20
different actions filed in 10 different
districts based upon alleged injuries
resulting from oral contraceptives
manufactured by defendant G.D. Searle
& Company. After citing the legislative
history expressly listing product-liability cases among possible MDL candidates, the panel noted the “existence
of several groups of product-liability
litigation during the past two years.”
Having become aware of the multiple
claims against G.D. Searle, the panel
itself initiated the MDL proceedings by
entering an order directing the parties
to show cause why the cases should not
be transferred for consolidated pretrial
proceedings. Ordinarily, this number
and dispersion of cases would have
justified consolidation, based upon the
Harvard Law Review study. In response
to the panel’s show-cause order,
however, the parties stated that there
were few if any common questions of
law or fact and that the transfer of the
cases would not serve the convenience
of the parties or witnesses. The panel
refused to transfer.
One can read the panel’s decision in
In re Oral Contraceptives in one of two
ways. By its action, as well as the lack
of other product-liability cases at the
time, the panel could be seen as having
doubts as to whether mass-tort cases
were appropriate for consolidation
under Section 1407. The other reading
— probably the more likely given the
radical increase over time of precisely
these sorts of mass-tort claims being
consolidated — is that the panel was
expressing its opinion that this was an
area where MDL consolidation should
be expanded. The opinion goes out of
its way to make the point that the panel
was aware of the existence of these types
of product-liability cases. It also made
clear that its decision to deny transfer
was a function of the views expressed by
the parties and was without prejudice to
reconsidering the issue at a later time.6
The main gist of the Harvard Law
Review study was that the panel was

aggressively using Section 1407. The
panel had expressed a strong preference
for consolidation even in cases in which
there were noncommon facts or a small
number of actions. As long as there
were significant common issues, the
panel was likely to grant consolidation.
For example, with respect to air disaster
litigation — the primary type of mass
tort generally recognized at the time
— consolidation was routinely granted
unless discovery in the actions was
close to completion.7 The panel, driven
by its charge for achieving judicial
efficiency, liberally granted consolidation under Section 1407 sometimes
even in the face of objections by the
parties to the litigation.
Rather than set a high threshold for
the number of filings needed to justify
consolidation, the study found that the
panel regularly ordered consolidation
if there were more than five actions
involved (a far cry from the described
justification of “massive filings”). The
In Re Oral Contraceptives decision was
one of only two cases involving more
than five actions where transfer was
denied based upon a finding of an
absence of common facts.
The study also noted that from the
beginning of the MDL process, transferee judges as well as the panel itself
demonstrated an interest in resolving
the cases as opposed to remanding them
to the districts in which they were originally filed. Only some of the resolutions
were expressly based upon existing
pretrial procedures. On occasion, for
example, transferee judges granted
motions to dismiss or motions for
summary judgment (pretrial procedures
that were clearly within the purview of
pretrial procedures that the transferee
judge was expected to utilize). But
use of such motions was usually only
to “simplify litigation by eliminating
certain issues or cases and only rarely to
dispose of an entire group of cases.” The
study noted only a single instance when
a transferee judge had granted summary
judgment on the basic common issue at
the end of pretrial.8
While there was nothing controversial about the use of existing pretrial
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motions, transferee judges — with the
support of the panel — also took other
steps to avoid remanding. Most notable
was the use of Section 1404(a), by
which some judges entered orders transferring cases to their districts for the
purpose of trying the case and imposing
final judgment. While the practice
of retaining cases for trial rather than
remanding to the transferor court was
controversial, there was substantial
support for the practice based upon efficiency considerations.9 Ultimately, the
Supreme Court held that this approach
was inconsistent with the plain meaning of Section 1407, especially in light
of the relevant legislative history.10
The Harvard Law Review study also
made clear that many MDL dockets resulted in settlements achieved
through the efforts of the transferee
court. For example, in antitrust cases
following a successful government prosecution, the main issue was to determine damages as opposed to liability
(which had already been established). In
those cases, settlements were common
without the need for remand.
Evolution of the MDL Process
Since the early 1990s and the Harvard
Law Review study, MDL practices have
continued to evolve and gradually
expand. An article published as part of
a symposium on multidistrict litigation by Judge John Heyburn, chair
of the Judicial Panel on Multidistrict
Litigation between 2007 and 2014,
provides an excellent overview of the
state of MDL affairs as of 2008.11 As
of that date, the panel had considered motions in nearly 2,000 dockets
involving a quarter-million cases (likely
involving millions of claims).
The workload of the panel has
gradually increased over time. In 1996,
the panel for the first time considered
more than 60 requests for consolidation; in 2007, the panel considered
almost 100 claims. As of 1997, there
were 161 open MDL dockets encompassing 54,000 actions. Ten years later,
the number of open MDL dockets had
increased to 297, encompassing over
76,000 pending actions.12
4
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In his analysis of the panel’s workload, Judge Heyburn made the special
point to challenge the “common misconception” that the MDLs are mostly
“mega-cases.” He noted that there were
indeed some “mega-cases” in the MDL
process, but that the large majority
of MDLs did not fit that description.13
As of 2008, only 37 out of about 300
active MDLs comprised more than 100
constituent actions, while only 10 had
more than 1,000. He referenced three
mass-tort cases dealing with asbestosis claims (42,000 pending actions at
the time), Vioxx claims (9,300 pending
actions in which the judge had recently
approved a settlement), and Seroquel
claims (5,600 pending claims). In
contrast, he noted that about half of all
MDLs had 10 or fewer actions. Judge
Heyburn reiterated the commonly made
point that MDL dockets encompassed a
wide variety of litigation categories.
He did point out that recent developments limiting the use of class actions in
mass litigation perhaps created the possibility of greater use of MDL procedures
for such claims. As class-action devices
became less available or desirable, “some
litigants may be turning to the MDL
processes as a way of achieving some
of the benefits or advantages formerly
available under Rule 23.”14 This prediction proved to be on the money as one
looks to the present composition of MDL
dockets, which have come to be dominated by mass-tort cases.
Contemporary MDL Proceedings and
the Ascendancy of Mass Torts
In looking at the most recent six years
of MDL activity following the overview
described by Judge Heyburn, MDL
activity at first glance seems to have
reached a plateau. The high-water mark
for MDL docket requests occurred
in 2009, when for the first time, the
number of requests topped the century
mark with 121 new docket requests.
After a dip in 2010 (84 new docket
requests), it again surpassed 100 new
dockets in 2011. In the following three
years, new docket requests have been
stable, averaging about 90 requests per
year (which is essentially at the same

					

level as the last few years documented
by Judge Heyburn).15
More noteworthy, however, is that
significantly fewer new MDL docket
requests have been granted recently,
with a corresponding increase in denials
of MDL status. While the number of
new MDL dockets in 2009 (83 new
dockets granted) almost equaled the
record 85 docket requests granted in
2008, the number of new dockets has
declined dramatically since then and
is now at the levels of the early 2000s.
From 2010 to 2014, a total of 241
MDL docket requests were granted (on
average 48 per year). During that same
period, the denial rate for MDL dockets
increased, as a total 160 MDL docket
requests were denied (averaging 32 per
year). The overall grant rate during
this period was a historically low 60
percent. By way of comparison, for
the previous five-year period covering
2005–2009, the panel granted MDL
docket requests in 327 cases and denied
requests in only 52 cases for a grant
rate of 86 percent.
But what can be said about any
changes in the type of cases subject to
MDL treatment? For the past couple of
years, annual statistics published by the
JPML have shown the distribution of the
types of cases for pending MDL dockets. The data initially seems to confirm
the conventional wisdom that the MDL
process ranges broadly across many types
of litigation, with a few areas of concentration. The statistics focusing solely on
the number of MDL dockets show that
there are many types of cases that are
subject to MDL treatment. But there
is a flip side to this coin that tells a
very different story if one focuses more
on the number of pending actions that
comprise those MDL dockets.
If one were to think about the faces
carved on to an MDL Mt. Rushmore,
it would certainly include antitrust
and securities actions as long-standing
major categories of litigation regularly
achieving MDL status. The 64 antitrust
dockets constitute close to 22 percent of
the pending MDL dockets (a percentage
markedly similar to what was found in
the earliest Harvard Law Review study).
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Securities would be a lesser figure, but
this category still constitutes a durable 10 percent of the MDL docket.
Competing for a possible position would
likely be sales practices (constituting 12
percent of the dockets) or intellectual
property cases (which has slipped to only
6 percent of the MDL docket).
The main nominees for the remaining “monument” status would be products liability (with 70 MDL dockets or
24 percent of the total) and the somewhat mysterious miscellaneous category
with 49 dockets (17 percent of the
total). Since the MDL statistics do not
have a specific category for mass torts
per se, if one were interested in assessing the impact of MDL litigation on
mass-tort claims, it would be necessary
to examine whether the largest category of cases — product liability — is
comprised primarily of mass-tort cases
or other types of product-liability cases.
One might even reach a preliminary
conclusion that there has been a decline
of sorts as it relates to at least some
categories of cases most often associated with mass tort. The number of air
disaster and common disaster cases (two
of the nine specific categories that the
MDL statistics track) has shrunk to the
bottom of the list, with only three and
two MDL dockets respectively constituting a paltry 2 percent of pending
dockets. These categories historically
— especially during the early years of
the MDL process — constituted a much
more significant part of the workload.
Mass Torts Dominate MDL Dockets
In drilling down into the current state
of pending MDL dockets, it is possible
to tell a very different story about the
current state of MDL practice. Rather
than being a process that is regularly
used across a wide range of litigation
types, it is in fact dominated by masstort cases at a remarkable level. The
JPML statistics that simply report an
overview of the mere number of MDL
dockets disguise that incredible concentration of mass-tort actions through the
MDL process.
The primacy of mass-tort claims in
the MDL process can be demonstrated
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personal injury). In
contrast to the masstort product claims,
CATEGORY # of MDL Dockets		Pending Actions Historical Actions
the number of actions
Common Disaster
2
2,964
3,111
in these non-massAir Disaster
3
29
108
tort product claims
was modest, with the
Miscellaneous
7
2,558
2,636
exception of the Toyota
Product Liability
55
119,667
393,209
Acceleration MDL
(Mass Tort only)				
Docket that included
TOTAL:
67
125,218
399,064
88 actions.17 Three
other MDL dockets
by looking more carefully at the current dealt with other types of property
cases. Using the JPML’s March 16,
damage.18 Collectively, these 16 MDL
2015, report (most recent as of the time dockets constituted only 561 pending
of the writing of this article), one can
civil actions. Only two of the dockets
examine in detail the 287 MDL dockets included more than 25 actions. The
to determine which dockets fall within median number of actions per docket for
the mass-tort category. The results
these “non-mass-tort” product-liability
are stunning: mass-tort MDL dockets
cases was only 12 actions.
consolidated over 125,000 civil actions
The remaining 55 product-liability
constituting over 96 percent of all
cases involve claims fairly described
pending actions included in all of the
as mass-tort claims. These claims
MDL dockets.
include numerous MDL dockets against
To develop a comprehensive list of
suppliers of medical devices such as
mass-tort claims, one first includes
artificial hips, as well as claims against
the small number of dockets included
pharmaceutical companies for alleged
in the air disaster and common disasinjuries resulting from drugs. Overall,
ter categories. The three air disaster
these 55 MD mass-tort product-liabildockets involve relatively few pending
ity dockets consolidated nearly 120,000
actions. The common disaster category
pending civil actions. While 20 of the
which includes the Deepwater Horizon cases currently involve fewer than 100
MDL with 2,941 pending actions —
current consolidated actions (probahas considerably more actions.
bly because the matters are in the last
It is then necessary to review the
stages of resolution), most have historproduct-liability cases closely, as not all ically involved hundreds and indeed
product-liability cases involve massusually thousands of actions. The
tort claims. A careful review of the
historical total of actions consolidated
product cases reveals that 16 of the 71
in these 55 product-liability cases is
product-liability MDLs are not massover 390,000 actions.19
tort claims. For example, nine of the
To determine the full range of massMDL dockets involve claims against
tort MDL dockets, it is also necessary
building supply companies whose
to peruse the miscellaneous category.
products (windows, shingles, decking,
It contains some of the new types of
or cement siding) were defective but
litigation that are constantly developwere not alleged to have caused any
ing within the U.S. litigation system.
16
personal injury. Three other MDL
For example, the pending list includes
dockets involved product-liability
a number of dockets involving claims
claims based upon alleged defects in
against companies such as Target and
engines. There were four other MDL
Sony for damages related to security
dockets alleging damage to products
breaches. The category also includes
such as mold in washing machines,
a variety of claims based upon unfair
an herbicide that damaged trees, or
business practices relating to mortproducts that contaminated well water
gages. But the MDL miscellaneous
(but not alleged to have caused any
category also includes a number of
MASS-TORT MDL DOCKETS (as of March 16, 2015)
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mass-tort claims, such as the highprofile National Football League
concussion cases (and similar claims
filed against the National Hockey
League and the National Collegiate
Athletic Association). Overall there are
seven MDL dockets in the miscellaneous category that are fairly characterized as mass-tort claims. They include a
total of 2,558 pending civil actions.
MDL Mass-Tort Docket Statistics
Table 1 (at left) is a summary of the
current MDL dockets composed of
cases from four different categories:
(1) common disaster; (2) air disaster;
(3) those product-liability dockets
that involve mass-tort claims; and
(4) those miscellaneous dockets that
involve mass-tort claims. The results
are, again, stunning: There are a total
of 67 MDL mass-tort dockets (23
percent of the total MDL dockets).
Numerically, this is the largest category of MDL dockets (with a few more
dockets than in the antitrust category).
But the true MDL dominance of mass
torts is revealed when one examines the
number of pending actions contained in
those dockets. Those 67 MDL dockets
include almost 125,000 pending civil
actions. In comparison, the remaining
non-mass-tort MDL dockets account for
only about 6,000 pending cases. Thus,
the mass-tort MDL dockets comprise
an amazing 96 percent of the actual
actions covered by MDL consolidations.
In stark contrast to the non-mass-tort
product claims or other MDL dockets
that typically have relatively few claims,
there are numerous mass-tort MDL
claims with huge numbers of consolidated actions. Table 2 (next page) is a
list of the 23 MDL mass-tort dockets
as of March 16, 2015, that include over
1,000 pending civil actions.
The incredible concentration of
MDL pending actions in several large
mass-torts cases represents an important trend. According to statistics
published by the Center for Judicial
Studies at Duke Law School, prior to
2004, there were only a couple of large
MDL dockets (defined as including
more than 1,000 pending actions)
4
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(representing nearly
75 percent of the MDL
pending actions during
this time period). The
Historical Actions
above analysis for the
24,220
most recent information
19,600
shows that the ascen15,700
dency and concentration
of “large” MDL mass10,823
tort documents have
7,240
continued and indeed
9,395
accelerated.
4,286
Nor has the recent
11,801
increase in MDL denials
3,083 (CD)
mitigated the growth
in mass-tort dockets.
2,926
With a few minor
2,387
exceptions, the denials
2,197 (Misc)
have occurred in patent
2,082
or consumer cases
2,011
involving relatively
2,458
few potential cases to
consolidate. For exam1,863
ple, from Oct. 1, 2013,
2,597
through Sept. 30, 2014,
192,049
the panel denied consol5,277
idation in 27 dockets.21
1,234
The vast majority of
1,174
denials came in nontort
1,579
areas such as labor and
employment disputes,
1,110
patent cases, or nontort
327,092
product-liability cases.
Only three of dockets involved claims
that could be considered as potential
mass torts. Each of the dockets was
comprised of a small number of cases
(averaging nine cases per docket), and
presented unusual facts. For example,
in one of the denied dockets involving
the Mirena intrauterine device (IUD),
the panel refused consolidation of nine
cases filed by the same attorney that
claimed neurological injuries distinct
from the type of injury commonly
alleged in an existing MDL docket.
None of the MDL denials was in a
docket with more than ten cases alleging tort claims.
It may well be that growth in masstort MDLs is perfectly consistent with
the origins of the MDL process. Many
of the mass-tort claims present the
type of “massive-filing” cases that gave

MASS-TORT PENDING MDL DOCKETS WITH 1,OOO OR MORE
PENDING ACTIONS (as of March 16, 2015; all Product Liability unless noted)
MDL #

Short Name

Pending Actions

2327

Ethicon, Inc.

23,569

2325

American Medical

19,093

2326

Boston Scientific

15,429

2187

C.R. Bard

10,525

2244

DePuy Orthopaedics

7,147

2197

DePuy Orthopaedics

6,819

2299

Actos (Pioglitazone)

4,130

2100

Yasmin

3,502

2179

Deepwater Horizon

2,941

2428

Fresenius GranuFlo

2,925

2441

Stryker Hip Implant

2,316

2433

Du Pont C-8 (drinking water)

2,191

2502

Lipitor

2,079

2387

Coloplast Corp

1,870

2391

Biomet Hip Implant

1,863

1964

NuvaRing

1,739

2385

Pradaxa

1,647

875

Asbestos

1,510

1871

Avandia

1,332

2434

Mirena IUD

1,212

2545

Testosterone Replacement

1,172

2272

Zimmer NexGen Knee

1,090

2308

Skechers Shoe

1,038

TOTAL:

23 CASES

117,139

outside of the asbestos cases.20 Thus,
for the years 1999-2003, there were
only one or two non-asbestos “large”
MDL dockets that included on average a total of about 3,800 pending
actions consolidated through the MDL
process. These few MDL dockets had
only about 9 percent on average of the
total MDL pending actions. In the last
ten years, the concentration of the large
MDL cases — virtually all of which are
mass-tort cases — has risen exponentially. Thus, the same statistics from
the Center for Judicial Studies show
that for the years 2011–2014, there
were on average 15 large MDL dockets
with more than 1,000 pending actions
and that those MDL dockets were, on
average during this period, composed
of nearly 65,000 pending actions
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rise to the initial MDL legislation.
Handling cases with literally thousands
of claims indeed raises the specter of
overburdened courts grappling with
massive, duplicative discovery proceedings. So, even though Congress had not
specifically anticipated the onslaught of
mass-tort cases in its present form, the
MDL process is arguably well suited to
the development.
But what is also clear is that the
MDL process has important implications for how cases are managed. What
was initially designed as a simple
procedure for coordinating discovery is
obviously much more than that today.
As Judge Alex Kozinski wrote in his
dissent to the Ninth Circuit’s decision in Lexicon, “[t]he simple reality
is that once a case is sucked into the
MDL vortex, it seldom comes back.”22
While the Supreme Court has limited
what Kozinski called the federal court’s
“remarkable power grab” by limiting
the use of transferee courts transferring
actions to their own courts, the fact
remains that the vast majority of cases
transferred through the MDL are never
remanded back to where they were
filed. Instead, the cases are most often
resolved through settlement as part of
the MDL proceedings.
It is impossible to view the MDL
process as a neutral procedure designed
simply to achieve discovery efficiencies.23 From the beginning, the MDL
process did more than that. The
development represents more than a
simple “power grab” by some transferee
judges. It also reflects the evolution and
expansion of what constitutes “pretrial”
procedures since the time when Section
1407 was enacted. Not only have discovery practices radically evolved over time
(requiring far more judicial supervision
controlling perceived discovery abuse as
well as dealing with the development of
e-discovery), but numerous other changes
have radically redefined the role of the
judge in managing the pretrial process.
Consider just a few important
changes that impact pretrial procedures: The Supreme Court reinvigorated
summary judgment in the 1980s and
more recently refined how district courts
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are to examine motions to dismiss. The
Court also imposed important gatekeeping obligations on the district court
to review the reliability of opposing
parties’ expert witnesses. The role of the
judge in actively managing the settlement process also has greatly evolved
over this period. The use of courtordered ADR was unheard of at the
time of the enactment of Section 1407.
The point is simply that what was
initially thought of as the purpose of
the MDL process — coordination of
“depositions and discoveries” — is in
fact much more than that.
Conclusion
The conventional wisdom has long
been that MDL has continually
expanded since its inception and that it
has come to play an important — and
increasingly controversial — role in
American litigation. It has never been
limited to situations with “massive
filings,” but rather was a procedural
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reality with respect to mass-tort claims
is radically different. The MDL process
has come to be dominated by large
mass-tort dockets typically involving thousands of underlying actions.
Indeed, over 95 percent of the total
actions currently consolidated through
the MDL process are mass-tort cases.
This represents a significant evolution
in the utilization of the MDL process
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Any hesitancy or concern with the
appropriateness of MDL treatment is
now certainly a relic of the past. The
MDL process has indeed become a
vortex with respect to mass torts. This
is not necessarily a problem or wrong
— indeed it is arguably fully consistent with original conceptualization
of the MDL process. But given the
reality that well over 100,000 masstort actions are currently consolidated
through the MDL process, it is important to examine carefully and critically
how the MDL works.
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